- Previous Close
2.0000 - Open
1.9900 - Bid 1.9300 x 200
- Ask 2.0000 x 100
- Day's Range
1.9200 - 2.0200 - 52 Week Range
1.5500 - 20.2200 - Volume
219,200 - Avg. Volume
230,463 - Market Cap (intraday)
98.118M - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
www.hillevax.comRecent News: HLVX
View MorePerformance Overview: HLVX
Trailing total returns as of 1/14/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HLVX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HLVX
View MoreValuation Measures
Market Cap
98.12M
Enterprise Value
-66.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.53
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.90%
Return on Equity (ttm)
-62.24%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-150.28M
Diluted EPS (ttm)
-3.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
189.31M
Total Debt/Equity (mrq)
13.55%
Levered Free Cash Flow (ttm)
-85.4M